We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-2.03%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.48B
AUM Growth
-$380M
Cap. Flow
-$210M
Cap. Flow %
-8.45%
Top 10 Hldgs %
29.58%
Holding
106
New
13
Increased
24
Reduced
44
Closed
23

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$67.1M
2
CI icon
Cigna
CI
+$59.2M
3
UNH icon
UnitedHealth
UNH
+$55.2M
4
HUM icon
Humana
HUM
+$51.8M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$46.7M

Top Sells

Rank Stock Value
1
GEHC icon
GE HealthCare
GEHC
+$84.9M
2
ABBV icon
AbbVie
ABBV
+$69.8M
3
BIO icon
Bio-Rad Laboratories Class A
BIO
+$57.9M
4
COR icon
Cencora
COR
+$57.7M
5
ARGX icon
argenx
ARGX
+$50.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRNX icon
51
Crinetics Pharmaceuticals
CRNX
$8.88B
$18.1M 0.73%
+610,000
New +$12.6M
IMCR icon
52
Immunocore
IMCR
$1.7B
$18.1M 0.73%
348,200
-226,800
-39% -$13.4M
ROIV icon
53
Roivant Sciences
ROIV
$24.3B
$17.6M 0.71%
1,503,302
-184,198
-11% -$2.08M
ANTX icon
54
AN2 Therapeutics
ANTX
$169M
$17.5M 0.71%
1,089,400
+432,200
+66% +$4.89M
PHAT icon
55
Phathom Pharmaceuticals
PHAT
$930M
$16.8M 0.68%
1,617,300
-332,400
-17% -$4.56M
DNTH icon
56
Dianthus Therapeutics
DNTH
$5.55B
$16.6M 0.67%
+1,217,554
New +$15.3M
FUSN
57
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$15M 0.61%
5,781,850
+81,850
+1% +$262K
CERE
58
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$14M 0.57%
643,000
+141,800
+28% +$3.55M
VRNA
59
DELISTED
Verona Pharma
VRNA
$13.5M 0.55%
830,300
-124,200
-13% -$2.39M
VTYX
60
DELISTED
Ventyx Biosciences
VTYX
$12.3M 0.5%
354,900
-337,600
-49% -$11.7M
NTLA icon
61
Intellia Therapeutics
NTLA
$1.52B
$12M 0.48%
379,100
-16,755
-4% -$650K
TVTX icon
62
Travere Therapeutics
TVTX
$5.2B
$11.8M 0.48%
+1,323,000
New +$18.7M
SDGR icon
63
Schrodinger
SDGR
$1.14B
$11.3M 0.45%
399,000
+124,100
+45% +$5M
KPTI icon
64
Karyopharm Therapeutics
KPTI
$161M
$11.1M 0.45%
553,238
-4,769
-0.9% -$107K
RYZB
65
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$11.1M 0.45%
+500,000
New +$10.5M
XENE icon
66
Xenon Pharmaceuticals
XENE
$6.28B
$11M 0.44%
321,400
-159,900
-33% -$5.98M
PACB icon
67
Pacific Biosciences
PACB
$432M
$8.64M 0.35%
1,034,294
-3,303,106
-76% -$37.7M
ACIU icon
68
AC Immune
ACIU
$236M
$8.46M 0.34%
2,969,800
+66,522
+2% +$203K
COLL icon
69
Collegium Pharmaceutical
COLL
$1.16B
$7.83M 0.32%
350,200
-3,900
-1% -$88.9K
ALPN
70
DELISTED
Alpine Immune Sciences Inc
ALPN
$7.53M 0.3%
657,280
-401,220
-38% -$4.94M
KZR
71
DELISTED
Kezar Life Sciences
KZR
$7.15M 0.29%
601,110
-6,890
-1% -$122K
SYRS
72
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$6.25M 0.25%
1,581,142
+117,108
+8% +$438K
GRTS
73
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$4.7M 0.19%
2,733,800
-31,700
-1% -$56.3K
ATEC icon
74
Alphatec Holdings
ATEC
$1.43B
$4.01M 0.16%
309,400
-83,600
-21% -$1.31M
NSTG
75
DELISTED
NanoString Technologies, Inc.
NSTG
$3.95M 0.16%
2,299,100
-401,300
-15% -$1.22M
1 2
3
4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q3 2023 Portfolio in Review

As of Q3 2023, Avidity Partners Management held 106 positions worth $2.48B, down 13% from $2.86B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Avidity Partners Management withdrew a net $210M in Q3 2023, closing 23 positions and reducing 44 holdings. Its most notable exit was GE HealthCare, an estimated $84.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology.

Against the trend, Avidity Partners Management opened a new position in Cigna worth $59.4M.

  • Avidity Partners Management's largest Q3 2023 buy was Cigna: 207,700 shares worth $59.4M.
  • Avidity Partners Management added most to Boston Scientific in Q3 2023, an estimated $67.1M increase.
  • Avidity Partners Management's biggest Q3 2023 reduction was argenx, cutting an estimated $50.7M.
  • Avidity Partners Management fully exited GE HealthCare in Q3 2023, selling an estimated $84.9M.
  • Avidity Partners Management's ten largest holdings make up 30% of its $2.48B portfolio in Q3 2023.
  • Avidity Partners Management opened 13 new positions and closed 23 in Q3 2023.
  • Avidity Partners Management's portfolio value fell 13% quarter-over-quarter to $2.48B.

Based on Avidity Partners Management's 13F filing for Q3 2023, filed 14 Nov 2023.